RxDoctor Payments Data

Stephen Hanna, MD

Cardiology · Easton, MDNPI 1164535894

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Abbott at 36.9% of the total. Reporting peaked in 2019 at $492 and has fallen 63.5% since, to $180 in 2024.

$1,383in general payments, 2019–2025

Across 36 payments — averaging $38.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$511
  • Medtronic$453
  • Irhythm Technologies, Inc.$135
  • Amgen$130
  • Pfizer$64
  • E.r. Squibb & Sons, L.L.C.$35
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$1,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott11$511
Medtronic(2 entities)6$453
Irhythm Technologies, Inc.7$135
Amgen3$130
Pfizer4$64
E.r. Squibb & Sons, L.L.C.2$35
Merck1$21
Novartis1$18
Johnson & Johnson1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 70th percentile of 44 cardiology providers in Maryland.

See all cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$340,774
Medicare patients
2,055
Services billed
4,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban294$284,605
XareltoRivaroxaban109$109,509
EntrestoSacubitril/Valsartan80$78,431
JardianceEmpagliflozin56$42,225
Metoprolol Succinate399$7,137
BrilintaTicagrelor11$5,814
Atorvastatin Calcium407$4,898
Rosuvastatin Calcium132$2,997
Icosapent Ethyl17$2,393
Ezetimibe52$2,166
Chlorthalidone113$2,111
Losartan Potassium206$1,852
Amiodarone Hcl76$1,762
Carvedilol168$1,487
Furosemide194$1,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$284,605294 claims
Johnson & JohnsonXarelto$17$109,509109 claims
NovartisEntresto$18$78,43180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 cardiology providers in Maryland.

Other cardiology in Easton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →